Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720278 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 526
- Enrollment target
NCT00720278: Completed Phase 3 study, sponsored by Meda Pharmaceuticals.
NCT00720278 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 526 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00720278, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 526 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if two allergy medications are more effective than placebo.
Primary Outcome
rTNSS consisting of runny nose, itchy nose, nasal congestion, and sneezing was assessed twice daily. Each symptom is rated on a scale from 0-3: 0=none, 1=mild, 2=moderate, and 3=severe. (maximum 12 points per assessment.) Total possible score is 24 per day. Least square means was controlled for study day as the within-patient effect, treatment group and site as the between-patient effects, treatment by-study day interaction, and baseline as a covariate.
Interventions
- DRUG Placebo
- DRUG 0.15% azelastine hydrochloride 1644 mcg daily
- DRUG 0.1% azelastine hydrochloride 1096 mcg daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 526 participants |
| Start Date | 2007-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 3 |
What the finished NCT00720278 record still lists
NCT00720278 is an interventional study that assigns participants to a tested intervention. The registered 526 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00720278 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00720278 about?
NCT00720278 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies". The purpose of this study was to determine if two allergy medications are more effective than placebo.
What is the current status of trial NCT00720278?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 526 participants. The study started on 2007-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00720278?
The interventions under investigation include: Placebo (DRUG), 0.15% azelastine hydrochloride 1644 mcg daily (DRUG), 0.1% azelastine hydrochloride 1096 mcg daily (DRUG).
Who is sponsoring clinical trial NCT00720278?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00720278's enrollment target sits among peer trials
526 715th of 2000 higher than 1,286 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04738825 · 526 participants · NA
Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With PrEP Adherence and Support Services
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia